Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Market Closed 12-20 16:00:00 EST

2.00

+0.16

+8.70%

盘后1.95

-0.05-2.50%

19:19 EST

High2.08	Low1.79	Vol680.00K
Open1.79	D1 Closing1.84	Amplitude15.76%
Mkt Cap62.10M	Tradable Cap44.78M	Total Shares31.05M
T/O1.34M	T/O Rate3.04%	Tradable Shares22.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":2,"timestamp":1734728400000,"preClose":1.84,"halted":0,"volume":679998,"hourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":2,"latestTime":"19:19 EST","volume":2102,"amount":4155.57,"timestamp":1734740353657},"delay":0,"floatShares":22390040,"shares":31050448,"eps":-1.965974,"marketStatus":"Market Closed","change":0.16,"latestTime":"12-20 16:00:00 EST","open":1.79,"high":2.08,"low":1.79,"amount":1335592.571775,"amplitude":0.157609,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.965974,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.79,"preClose":1.84,"latestTime":"09:24 EST","volume":12560,"amount":21965.632616,"timestamp":1734704664616},"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":2,"latestTime":"19:19 EST","volume":2102,"amount":4155.57,"timestamp":1734740353657},"volumeRatio":0.7763330692403603},"requestUrl":"/m/hq/s/IMRX/tweets","defaultTab":"tweets","newsList":[{"id":"2492205601","title":"Immuneering launches Pancreatic Cancer Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2492205601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492205601?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:15","pubTimestamp":1734614115,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX) Corporation announced the formation of its Pancreatic Cancer Advisory Board. The Company’s Pancreatic Cancer Advisory Board incl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-launches-pancreatic-cancer-advisory-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-launches-pancreatic-cancer-advisory-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4563","BK4139","IMRX"],"gpt_icon":0},{"id":"2492465127","title":"Immuneering Launches Pancreatic Cancer Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2492465127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492465127?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999777/0/en/Immuneering-Launches-Pancreatic-Cancer-Advisory-Board.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4563","IMRX","BK4139"],"gpt_icon":0},{"id":"2492495474","title":"Immuneering to present data from Phase 2a trial of IMM-1-104 in early January","url":"https://stock-news.laohu8.com/highlight/detail?id=2492495474","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492495474?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:11","pubTimestamp":1734441079,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX) will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104. Specifica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-to-present-data-from-phase-2a-trial-of-imm-1-104-in-early-january?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-to-present-data-from-phase-2a-trial-of-imm-1-104-in-early-january?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","IMRX","BK4139","BK4563"],"gpt_icon":0},{"id":"2492954981","title":"Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954981","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954981?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":"- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel  in first-line pancreatic cancer -. - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX  in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer -. CAMBRIDGE, Mass., Dec. 17, 2024  -- Immuneering Corporation , a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that it will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104.Additional data from IMM-1-104 in combination with mGnP in first-line pancreatic cancer.Initial data from IMM-1-104 in combination with mFFX in first-line pancreatic cancer.Initial data from IMM-1-104 monotherapy in second-line pancreatic cancer.In addition, the company will provide initial PK, PD and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fS0nW6gEvpTcVyJ6eCdxjw--~B/aD04MTM7dz0zMzAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c5aade0bb2afc0d11d8155eb3fc21e20","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fS0nW6gEvpTcVyJ6eCdxjw--~B/aD04MTM7dz0zMzAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c5aade0bb2afc0d11d8155eb3fc21e20"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immuneering-present-data-three-arms-130000719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","BK4539","IMRX","BK4139"],"gpt_icon":0},{"id":"2491302522","title":"Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491302522","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491302522?lang=en_us&edition=fundamental","pubTime":"2024-12-14 03:10","pubTimestamp":1734117050,"startTime":"0","endTime":"0","summary":"Morgan Stanley downgraded Amicus Therapeutics Inc . Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares.The analyst downgraded the stock to Equal-weight from Overweight and lowered the price target from $17 to $12.Investors have shifted focus to what will provide the company’s next leg of growth. The analyst would look to see potential updates to the company’s pipeline in 2025 and beyond, as those programs have the greatest potential to unlock further value for Amicus stock.Morgan Stanley has also lowered the price target for Immunocore Holdings plc  from $74 to $35 on launch timing and pricing for brenetafusp given disappointing data earlier this year in cutaneous melanoma","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uI4OafKdqumkkqx_HY1gvw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/83e707c5ba3952b58fca54fa366205fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uI4OafKdqumkkqx_HY1gvw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/83e707c5ba3952b58fca54fa366205fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-amicus-immunocore-immuneering-stocks-191050213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0098860793.USD","PSQ","LU2111349929.HKD","BK4127","LU0971096721.USD","BK4139","BK4581","BK4563","BK4539","TQQQ","LU2065170008.USD","LU2271345857.HKD","SQQQ","BK4504","LU0006306889.USD","FOLD","BK4588","NQmain","LU0320765646.SGD","LU1720051017.SGD","LU1989772840.SGD","LU2065171402.SGD","LU2089283258.USD","NVIW.SI","IMCR","LU1074936037.SGD",".IXIC","TSYW.SI","LU0158827781.USD","IE00BKVL7J92.USD","LU2065169927.USD","IE00BZ1G4Q59.USD","LU2089284900.SGD","LU0314104364.USD","LU1162221912.USD","BK4585","MNQmain","LU0106831901.USD","IMRX","LU0158827948.USD","BK4505","QLD","LU1363072403.SGD","LU0267386448.USD","QID","USAW.SI","USJW.SI","LU1989772923.USD","BK4534"],"gpt_icon":1},{"id":"2491326405","title":"Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5","url":"https://stock-news.laohu8.com/highlight/detail?id=2491326405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491326405?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:50","pubTimestamp":1734090619,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX) has an average rating of overweight and mean price target of $11.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMRX"],"gpt_icon":0},{"id":"2490637388","title":"Immuneering Granted FDA Fast Track Designation for Imm-1-104 in Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490637388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490637388?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:00","pubTimestamp":1734008401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA2DJB39:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2490388223","title":"Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490388223","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490388223?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:00","pubTimestamp":1734008400,"startTime":"0","endTime":"0","summary":"- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996132/0/en/Immuneering-Granted-FDA-Fast-Track-Designation-for-IMM-1-104-in-Advanced-Melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","IE0031619046.USD","FAST","IE00B19Z4B17.USD","BK4539","IE00B7SZL793.SGD","AEIS","BK4157","IE00B66KJ199.SGD","BK4139","BK4563"],"gpt_icon":0},{"id":"2483876123","title":"Cautious Hold Recommendation on Immuneering Amid Promising Developments and Financial Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876123?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:57","pubTimestamp":1731585451,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeffrey Hung from Mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-hold-recommendation-on-immuneering-amid-promising-developments-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-hold-recommendation-on-immuneering-amid-promising-developments-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","IMRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2483824216","title":"Immuneering Price Target Maintained With a $15.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2483824216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483824216?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:31","pubTimestamp":1731580260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 05:31 ET (10:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2483212118","title":"Immuneering’s Promising Outlook: Strong Clinical Progress and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2483212118","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483212118?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:16","pubTimestamp":1731579406,"startTime":"0","endTime":"0","summary":"Ami Fadia, an analyst from Needham, maintained the Buy rating on Immuneering (IMRX – Research Report). The associated price target remains the same...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immuneerings-promising-outlook-strong-clinical-progress-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immuneerings-promising-outlook-strong-clinical-progress-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","IMRX","LU2065732104.USD","BK4563","BK4539","BK4139","BK4097"],"gpt_icon":0},{"id":"2483865849","title":"Immuneering reports Q3 EPS (49c), consensus (55c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483865849","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483865849?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:30","pubTimestamp":1731533426,"startTime":"0","endTime":"0","summary":"Reports Q3 cash, cash equivalents and marketable securities as of September 30 were $50.7M , compared with $85.7M as of December 31, 2023. The Sept...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q3-eps-49c-consensus-55c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q3-eps-49c-consensus-55c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"gpt_icon":0},{"id":"2483868102","title":"Immuneering Q3 2024 GAAP EPS $(0.49) Beats $(0.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868102","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868102?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:10","pubTimestamp":1731532211,"startTime":"0","endTime":"0","summary":"Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 12.5 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41954328/immuneering-q3-2024-gaap-eps-0-49-beats-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immuneering Q3 2024 GAAP EPS $(0.49) Beats $(0.56) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2483863431","title":"Immuneering Corp: Cash Runway Into Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863431?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1YBXZ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","BK4563","IMRX"],"gpt_icon":0},{"id":"2483868596","title":"Immuneering Corporation Q3 Net Income USD -14.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868596?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXAD4FBE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","BK4563","IMRX"],"gpt_icon":0},{"id":"2483868598","title":"Immuneering Corporation Q3 EPS USD -0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868598?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXAD4FBE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4139","IMRX","BK4539"],"gpt_icon":0},{"id":"2476945329","title":"IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476945329","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476945329?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:24","pubTimestamp":1729088640,"startTime":"0","endTime":"0","summary":"Immuneering Corporation IMRX announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up 15.5% on Oct. 15 following the announcement of the news.The FDA grants Orphan Drug Designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The Orphan Drug Designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies as well as exemptions from certain FDA application fees.IMM-1-104 was earlier granted the FDA’s Fast Track designation in the United States for the treatment of first- and second-line pancreatic cancer.Year to date, shares of Immuneering have plunged 68.6% compared with the industry’s decrease of 1.8%.Last month, the company announced positive early response data from the first five patients of an ongoin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imrx-stock-fdas-orphan-drug-142400084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","VYGR","BK4539","ALNY","BK4139","BK4007","BK4563","BK4548","BK4585","ANIP","IMRX"],"gpt_icon":0},{"id":"2475330500","title":"Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2475330500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475330500?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:16","pubTimestamp":1728998166,"startTime":"0","endTime":"0","summary":"Immuneering  said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.The company said a phase 2a clinical trial to evaluate IMM-1-104 combined with chemotherapy in patients with advanced solid tumors, including pancreatic cancer, is ongoing.The company, which recently announced positive initial phase 2a results, said it expects to provide initial data from at least one additional arm of the phase 2a portion of its phase 1/2a trial before the end of the year.Shares of Immuneering advanced 23% in premarket activity Tuesday.Price: 2.4600, Change: +0.46, Percent Change: +23.00","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMRX","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2475450738","title":"Immuneering rises on orphan drug designation for treatment of pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475450738","media":"seekingalpha","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475450738?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:04","pubTimestamp":1728997456,"startTime":"0","endTime":"0","summary":"koto_feja  Immuneering Corporation (NASDAQ:IMRX) shares up 24.5% premarket after it announced that the U.S. FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623196413/image_1623196413.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623196413/image_1623196413.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4159870-immuneering-rises-on-orphan-drug-designation-for-treatment-of-pancreatic-cancer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4007","BK4584","BK4557","SQQQ","NQmain","BK4588","BK4559","BK4563","MNQmain","QID","BK4585","BK4139","BK4566","QLD","BK4539","IMRX","PSQ","TEVA",".IXIC","TQQQ"],"gpt_icon":0},{"id":"2475506338","title":"Immuneering granted Orphan Drug Designation for IMM-1-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2475506338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475506338?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:21","pubTimestamp":1728994864,"startTime":"0","endTime":"0","summary":"Immuneering announced that the U.S. Food and Drug Administration has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-granted-orphan-drug-designation-for-imm-1-104?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-granted-orphan-drug-designation-for-imm-1-104?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4563","IMRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":0.2232},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.3769},{"period":"6month","weight":0.3986},{"period":"1year","weight":-0.7135},{"period":"ytd","weight":-0.7279}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.239671},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.009906},{"month":3,"riseRate":0.333333,"avgChangeRate":0.105982},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.203232},{"month":5,"riseRate":0,"avgChangeRate":-0.137963},{"month":6,"riseRate":0.666667,"avgChangeRate":0.145613},{"month":7,"riseRate":0.666667,"avgChangeRate":0.029987},{"month":8,"riseRate":0.25,"avgChangeRate":0.029018},{"month":9,"riseRate":0.75,"avgChangeRate":0.686735},{"month":10,"riseRate":0.25,"avgChangeRate":-0.087438},{"month":11,"riseRate":0.25,"avgChangeRate":-0.159888},{"month":12,"riseRate":0.25,"avgChangeRate":-0.115198}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}